3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Melanoma
8
Uveal Melanoma
3
Multiple Myeloma
2
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Rhabdomyosarcoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Eye Neoplasms
1
Interventions
Cyclophosphamide
53
Etoposide
33
Temozolomide
28
Irinotecan
28
Melphalan
25
Filgrastim
25
Topotecan
24
Carboplatin
24
3-Iodobenzylguanidine
23
Isotretinoin
20
Granulocyte Colony-Stimulating Factor
17
sargramostim
16
humanized 3F8 anti-GD2 monoclonal antibody
16
dinutuximab
16
Granulocyte-Macrophage Colony-Stimulating Factor
16
fludarabine
15
Vincristine
15
Doxorubicin
15
Cisplatin
15
Peripheral Blood Stem Cell Transplantation
14
Interleukin-2
14
Busulfan
13
naxitamab
12
Thiotepa
12
Radiotherapy
12
aldesleukin
11
fludarabine phosphate
10
etoposide phosphate
8
Mesna
8
Ifosfamide
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroblastoma
×
MAGEA3 protein, human
×
Clear all
NCT00944580
2017-11-24
A Vaccine Study for High Risk Cancers
Penn State University
Phase 1
Withdrawn